BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 36960538)

  • 1. Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis.
    Wang J; Li YY; Lin MJ; Liu J; Lin BS; Ding YM; Wan M; Zhang WL; Kong QZ; Wang ST; Mu YJ; Duan M; Han ZX; Zuo XL; Li YQ
    J Dig Dis; 2023 Jan; 24(1):19-27. PubMed ID: 36960538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
    Furuta T; Yamade M; Kagami T; Uotani T; Suzuki T; Higuchi T; Tani S; Hamaya Y; Iwaizumi M; Miyajima H; Umemura K; Osawa S; Sugimoto K
    Digestion; 2020; 101(6):743-751. PubMed ID: 31434101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?
    Dong SQ; Singh TP; Wei X; Yao H; Wang HL
    Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28884937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: A propensity score matching analysis.
    Liu Z; Chen X; Sun DJ; Zhao WW; Kou L; Zheng WW; Hao JR; Gao FY
    Medicine (Baltimore); 2024 Mar; 103(10):e37476. PubMed ID: 38457567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol.
    Han S; Deng Z; Cheung K; Lyu T; Chan P; Li Y; Ni L; Luo X; Li K
    BMC Gastroenterol; 2023 Jul; 23(1):231. PubMed ID: 37420205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
    Maruyama M; Tanaka N; Kubota D; Miyajima M; Kimura T; Tokutake K; Imai R; Fujisawa T; Mori H; Matsuda Y; Wada S; Horiuchi A; Kiyosawa K
    Can J Gastroenterol Hepatol; 2017; 2017():4385161. PubMed ID: 28349044
    [No Abstract]   [Full Text] [Related]  

  • 7. A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study.
    Nishida T; Tsujii Y; Okamoto A; Tomita R; Higaki Y; Osugi N; Sugimoto A; Takahashi K; Mukai K; Nakamatsu D; Matsubara T; Hayashi S; Yamamoto M; Nakajima S; Fukui K; Inada M
    Digestion; 2020; 101(5):608-614. PubMed ID: 31288235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
    Lu L; Wang Y; Ye J; Han Y; Lou G; Li Y; Yan H; Du Q
    Helicobacter; 2023 Feb; 28(1):e12940. PubMed ID: 36458325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.
    Kim YI; Lee JY; Kim CG; Park B; Park JY; Choi IJ
    BMC Gastroenterol; 2021 Mar; 21(1):95. PubMed ID: 33653284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
    Kajihara Y; Shimoyama T; Mizuki I
    Scand J Gastroenterol; 2017 Feb; 52(2):238-241. PubMed ID: 27806639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials.
    Sun Y; Yue L; Hu W
    Eur J Clin Pharmacol; 2023 Feb; 79(2):279-288. PubMed ID: 36527456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
    Chen S; Shen W; Liu Y; Dong Q; Shi Y
    Chin Med J (Engl); 2023 Jul; 136(14):1690-1698. PubMed ID: 37469024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials.
    Yang C; Li S; Huang T; Lin H; Jiang Z; He Y; Yuan J; An H
    J Clin Pharm Ther; 2022 Jul; 47(7):897-904. PubMed ID: 35247003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vonoprazan-based therapies versus PPI-based therapies in patients with H. pylori infection: Systematic review and meta-analyses of randomized controlled trials.
    Liu L; Shi H; Shi Y; Wang A; Guo N; Li F; Nahata MC
    Helicobacter; 2024; 29(3):e13094. PubMed ID: 38790090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
    Qian HS; Li WJ; Dang YN; Li LR; Xu XB; Yuan L; Zhang WF; Yang Z; Gao X; Zhang M; Li X; Zhang GX
    Am J Gastroenterol; 2023 Apr; 118(4):627-634. PubMed ID: 36729890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study: Vonoprazan and proton pump inhibitors in
    Sakurai K; Suda H; Ido Y; Takeichi T; Okuda A; Hasuda K; Hattori M
    World J Gastroenterol; 2017 Jan; 23(4):668-675. PubMed ID: 28216974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis.
    Shinozaki S; Kobayashi Y; Osawa H; Sakamoto H; Hayashi Y; Lefor AK; Yamamoto H
    Digestion; 2021; 102(3):319-325. PubMed ID: 31914442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.
    Ang D; Koo SH; Chan YH; Tan TY; Soon GH; Tan CK; Lin KW; Krishnasamy-Balasubramanian JK; Wong YJ; Kumar R; R R; Tan Y; Ong PJ; Tan YJ; Li JW; Kwek AB; Ang TL
    Aliment Pharmacol Ther; 2022 Aug; 56(3):436-449. PubMed ID: 35665947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
    He XJ; Wang XL; Huang XY; Li DZ; Liu G; Wang W; Li DL
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102052. PubMed ID: 36400418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.